A detailed history of Price T Rowe Associates Inc transactions in Vaxart, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 78,500 shares of VXRT stock, worth $54,950. This represents 0.0% of its overall portfolio holdings.

Number of Shares
78,500
Previous 78,500 -0.0%
Holding current value
$54,950
Previous $52,000 28.85%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$0.6 - $1.41 $14,088 - $33,106
-23,480 Reduced 23.02%
78,500 $58,000
Q1 2023

May 15, 2023

BUY
$0.71 - $1.25 $15,975 - $28,125
22,500 Added 28.31%
101,980 $78,000
Q4 2022

Feb 14, 2023

BUY
$0.75 - $2.24 $3,132 - $9,354
4,176 Added 5.55%
79,480 $76,000
Q3 2022

Nov 14, 2022

SELL
$2.09 - $4.5 $184,158 - $396,513
-88,114 Reduced 53.92%
75,304 $165,000
Q2 2022

Aug 15, 2022

BUY
$2.7 - $5.28 $228,690 - $447,216
84,700 Added 107.6%
163,418 $572,000
Q1 2022

May 16, 2022

BUY
$4.29 - $6.64 $48,567 - $75,171
11,321 Added 16.8%
78,718 $397,000
Q4 2021

Feb 14, 2022

SELL
$5.77 - $7.96 $61,375 - $84,670
-10,637 Reduced 13.63%
67,397 $423,000
Q3 2021

Nov 15, 2021

SELL
$6.67 - $9.8 $110,722 - $162,680
-16,600 Reduced 17.54%
78,034 $620,000
Q2 2021

Aug 16, 2021

BUY
$5.06 - $10.78 $61,175 - $130,330
12,090 Added 14.65%
94,634 $709,000
Q1 2021

May 17, 2021

SELL
$5.64 - $23.33 $6.41 Million - $26.5 Million
-1,135,953 Reduced 93.23%
82,544 $499,000
Q4 2020

Feb 16, 2021

BUY
$3.5 - $7.98 $4.26 Million - $9.72 Million
1,218,497 New
1,218,497 $6.96 Million

Others Institutions Holding VXRT

About Vaxart, Inc.


  • Ticker VXRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 126,506,000
  • Market Cap $88.6M
  • Description
  • Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...
More about VXRT
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.